Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Cortical gray matter loss in schizophrenia: Could microglia be the culprit? (CROSBI ID 224015)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Rački, Valentino ; Petrić, Daniela ; Kučić, Natalia ; Gržeta, Nika ; Jurdana, Kristina ; Rončević-Gržeta, Ika Cortical gray matter loss in schizophrenia: Could microglia be the culprit? // Medical hypotheses, 88 (2016), 18-21. doi: 10.1016/j.mehy.2015.12.021

Podaci o odgovornosti

Rački, Valentino ; Petrić, Daniela ; Kučić, Natalia ; Gržeta, Nika ; Jurdana, Kristina ; Rončević-Gržeta, Ika

engleski

Cortical gray matter loss in schizophrenia: Could microglia be the culprit?

Cortical gray matter loss in schizophrenia remains a great therapeutic difficulty. Each psychotic episode causes irreversible cortical gray matter loss, that causes the patients to never regain their previous state of functioning. Microglial cells are part of the innate immune system and their functions, among others, include phagocytosis and release of neurotrophic factors. They have a key impact on developmental and plasticity-induced removal of neuronal precursors, live-but-stressed neurons and synapses, while also stimulating synaptic growth and development. We hypothesize that microglia are the culprit for the cortical gray matter loss in schizophrenia through abnormal synaptic pruning, phagocytosis of stressed neurons and lacking neurotrophic factor release. Furthermore, we propose a research that could validate the hypotheses using serum samples of first-episode early-onset patients. By measuring the serum levels of milk fat globule-EGF factor 8 (MFG-E8), subcomponent in the classical pathway of complement activation (C1q), brain-derived neurotrophic factor (BDNF), interleukin-6 (IL-6) and interleukin-10 (IL-10), we could gain an insight into the state of microglial activation during various stages of the disease. If this hypothesis is valid, new targeted drugs could be developed in order to reduce the deterioration of cortical gray matter, thereby possibly improving negative symptoms and cognitive deficits.

microglia ; schizophrenia ; neuroinflammation

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

88

2016.

18-21

objavljeno

0306-9877

10.1016/j.mehy.2015.12.021

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost